hOCT 1 and resistance to imatinib

被引：145

作者：

Crossman, LC ^{[1
]}

Druker, BJ ^{[1
]}

Deininger, MWN ^{[1
]}

机构：

[1] Univ Newcastle Upon Tyne, Sch Med, Newcastle Upon Tyne NE2 3QN, Tyne & Wear, England

来源：

BLOOD | 2005年 / 106卷 / 03期

关键词：

D O I：

10.1182/blood-2005-02-0694

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1133 / 1134

页数：2

共 6 条

[1] Pharmacokinetic resistance to imatinib mesylate - Role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib [J].

Burger, H ;

Nooter, K .

CELL CYCLE, 2004, 3 (12) :1502-1505

[2] Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump [J].

Burger, H ;

van Tol, H ;

Boersma, AWM ;

Brok, M ;

Wiemer, EAC ;

Stoler, G ;

Nooter, K .

BLOOD, 2004, 104 (09) :2940-2942

[3] Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux [J].

Dai, HQ ;

Marbach, P ;

Lemaire, M ;

Hayes, M ;

Elmquist, WF .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 304 (03) :1085-1092

[4] P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate [J].

Illmer, T ;

Schaich, M ;

Platzbecker, U ;

Freiberg-Richter, J ;

Oelschlägel, U ;

von Bonin, M ;

Pursche, S ;

Bergemann, T ;

Ehninger, G ;

Schleyer, E .

LEUKEMIA, 2004, 18 (03) :401-408

[5] MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models [J].

Mahon, FX ;

Belloc, F ;

Lagarde, V ;

Chollet, C ;

Moreau-Gaudry, F ;

Reiffers, J ;

Goldman, JM ;

Melo, JV .

BLOOD, 2003, 101 (06) :2368-2373

[6] Active transport of imatinib into and out of cells: implications for drug resistance [J].

Thomas, J ;

Wang, LH ;

Clark, RE ;

Pirmohamed, M .

BLOOD, 2004, 104 (12) :3739-3745

← 1 →